Skip to content

Clinical application of remazolam tosylate in gynecological day surgery

Clinical application of remazolam tosylate in gynecological day surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078737
Enrollment
Unknown
Registered
2023-12-18
Start date
2023-12-18
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group R:Remimazolam 0.25mg/kg
Group P:propofol 2mg/kg

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Elective gynecological day surgery ; aSA I-II ; bMI 18-28 ; women aged 18-65.

Exclusion criteria

Exclusion criteria: Patients with allergies to any component such as benzodiazepine opioids such as cyclopophenol mivacurium ; patients with schizophrenia and severe depression ; acute upper respiratory tract infection ; poorly controlled severe hypertension ; history of alcoholism and long-term use of sedative and analgesic drugs and history of allergies ; ma 's airway grade IV, which was determined by the researchers to require awake tracheal intubation ; lactating women ; other situations judged by the researcher to be unsuitable for selection ; the operation time was more than 1 hour. Patients hospitalized for more than 24 hours ; postoperative patients were lost to follow-up.

Design outcomes

Primary

MeasureTime frame
The success rate of induction of remazolam;

Secondary

MeasureTime frame
Incidence of adverse reactions;General information of patients;Time the patient fell asleep;Changes in hemodynamics at different times;time of waking;

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 135 6369 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026